Atara Biotherapeutics (ATRA) Raw Materials (2022 - 2024)

Atara Biotherapeutics (ATRA) has reported Raw Materials for 3 consecutive years, with $964000.0 the latest figure, recorded in Q4 2024.

• For the quarter ending Q4 2024, Raw Materials fell 58.72% year-over-year to $964000.0; the trailing twelve-month figure through Dec 2024 stood at $964000.0 (down 58.72% YoY), and the FY2024 full-year result was $964000.0, down 58.72% from the prior year.
• Raw Materials slipped to $964000.0 in Q4 2024 per ATRA's latest filing, from $1.7 million in the prior quarter.
• Across five years, Raw Materials topped out at $4.4 million in Q1 2024 and bottomed at $964000.0 in Q4 2024.
• Historically, Raw Materials has averaged $2.3 million across 3 years, with a median of $2.3 million in 2023.
• The widest YoY moves for Raw Materials: up 229.38% in 2024, down 58.72% in 2024.
• Over 3 years, Raw Materials stood at $1.2 million in 2022, then jumped by 92.34% to $2.3 million in 2023, then slumped by 58.72% to $964000.0 in 2024.
• According to Business Quant data, Raw Materials over the past three periods registered $964000.0, $1.7 million, and $3.6 million for Q4 2024, Q3 2024, and Q2 2024 respectively.